Cytek Biosciences

Cytek Biosciences EBIT per Share

The EBIT per Share of Cytek Biosciences (CTKB) as of Nov 1, 2026 is -0.32 USD. In the previous year, EBIT per Share was -0.16 USD — a change of 98.37% (lower).

EBIT per Share

-0.32USD

YoY

98.37%

Last updated:

EBIT per Share of Cytek Biosciences is 2025 -0.32 USD. EBIT per Share of Cytek Biosciences was 2024 -0.16 USD. It decreases by 98.37% lower compared to the previous year.

The Cytek Biosciences EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.21 USD
Jan 1, 2024
-0.16 USD
Jan 1, 2025
-0.32 USD
Jan 1, 2026 (e)
-0.34 USD
Jan 1, 2027 (e)
-0.25 USD
Jan 1, 2028 (e)
-0.21 USD
Jan 1, 2029 (e)
-0.07 USD
The Cytek Biosciences EBIT per Share history
YEAREBIT per ShareYoY
est-0.07USD-64.79%
est-0.21USD-16.55%
est-0.25USD-25.74%
est-0.34USD+6.35%
-0.32USD+98.37%
-0.16USD-25.43%
-0.21USD+1,518.03%
-0.01USD-116.34%
0.08USD-28.59%
0.11USD-186.97%
-0.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytek Biosciences Stock analysis

What does Cytek Biosciences do? Cytek Biosciences is a leading company in the cell analysis industry, offering advanced hardware and software-based solutions for biological research and diagnostics. The company was founded in 2011 by Dr. Wenbin Jiang and is headquartered in Fremont, California. The origins of Cytek can be traced back to 2002 when Jiang co-founded the company Dako Cytomation with Dr. Frank Fan. The company developed and produced products for cell analysis, including a new generation of cell counters and sorters. In 2010, Dako Cytomation was acquired by Agilent Technologies, and Jiang saw an opportunity to further expand his business model. In 2011, Jiang founded Cytek Biosciences with the aim of bringing a new generation of cell counters and sorters to the market that improve the performance and affordability of existing systems. With the acquisition of Now Bio in 2014, the company expanded its focus on developing new instruments and applications that can enhance the precision and efficiency of cell analysis. Cytek Biosciences primarily focuses on selling cell counters and sorters. In addition, the company also offers support services such as maintenance, repair, and training to ensure that customers can safely and effectively use their products. The customers of Cytek are primarily academic institutions, biotech companies, pharmaceutical companies, and government agencies involved in biological research and development. Cytek's products provide these customers with a powerful and cost-effective method of analyzing and sorting cells, increasing the efficiency and accuracy of their research work. Cytek Biosciences has several product lines tailored to different applications and customer needs. These include the Cytek Aurora, a complete spectral flow cytometer platform that can measure up to 50 channels simultaneously; the Cytek Northern Lights, a cost-effective spectral flow cytometer platform for cell analysis suitable for basic research and high-throughput screening; and the Cytek DxP Athena, a high-throughput sorting system that offers fast sorting speed and reduces the risk of cell damage and loss. In addition to these product lines, Cytek also offers a range of services including customer training, application development and support, as well as customer service and maintenance services for its products. In summary, Cytek Biosciences is a leading company in the field of cell analysis. It specializes in the development of cell counters and sorters that generate data with higher resolution and precision to enhance efficiency and accuracy in biological research and diagnostics. The company offers a variety of products and services to meet the needs of its customers. Cytek Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytek Biosciences stock

EBIT per Share of Cytek Biosciences is -0.32 USD in 2025.

EBIT per Share of Cytek Biosciences changed from -0.16 USD to -0.32 USD, representing a 98.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Cytek Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cytek Biosciences

All Key Metrics — Cytek Biosciences